An observational study in Central Neck Dissection and Papillary Thyroid Carcinoma, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Mansoura University · Observational
This study designed to examine the utility of prophylactic central neck dissection (CND) in the management of papillary thyroid carcinoma (PTC), to assess the association between risk factors as gender, age at diagnosis, and size of the tumor with performing central lymph node (CLN) affection, and to assess operative time, intraoperative and postoperative adverse events of CLN neck dissection.
Thyroid cancer is the most common endocrine cancer, contributing to 1-2% of all new malignancies diagnosed yearly worldwide.
The majority of thyroid carcinomas originate from follicular epithelial cells and include well-differentiated papillary thyroid carcinomas, up to 80% of all thyroid malignancies and follicular thyroid carcinomas about 15% of all thyroid malignancies. Moreover, undifferentiated anaplastic thyroid carcinoma 1-2% of all thyroid cancers, which is the most aggressive thyroid malignancy, also develops from epithelial cells.
Some authors recommend routine central LN neck dissection (CND) in thyroid cancer to prevent a future recurrence, citing the high risk of positive lymph nodes, better outcomes, and a lower morbidity rate associated with this initial operation, whereas others maintain that this procedure increases the risk of injury to the parathyroid glands and recurrent laryngeal nerves, with no demonstrable benefits in terms of long-term survival.
186 studies on the registry are indexed under Thyroid Cancer, Papillary; 51 are open to participants now.
This study's enrollment of 100 is below the median of 200 across 66 observational studies indexed under Thyroid Cancer, Papillary.
Browse Thyroid Cancer, Papillary studies →Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
In this prospective follow-up study, 100 patients with papillary thyroid carcinoma was included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients With Clinically Node-Negative Papillary Thyroid Carcinoma
Procedure: Thyroidectomy
Patients underwent total thyroidectomy with prophylactic bilateral central neck dissection.
Percentage of Participants With Histopathologically Confirmed Occult Central Lymph Node Metastasis
Percentage of participants with clinically and radiologically node-negative papillary thyroid carcinoma who have metastasis detected by histopathological examination of central compartment lymph nodes removed during prophylactic bilateral central neck dissection.
Time frame: 24 hours postoperatively
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in May 2023, 0 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.